The value of gonadotropin-releasing hormone-agonists together with other drugs for medical treatment and prevention

References

• Schindler AE. Clinical symptoms and hormones. Gynecol Endocrinol 2006;22:151–154.
   PubMed Web of Science ®Google Scholar
• Surrey ES, Hornstein MD. Prolonged GnRH agonist and add-back therapy for symptomatic endeometriosis: long-term follow-up. Obstet Gynecol 2002;99:709–719.
   PubMed Web of Science ®Google Scholar
• Fernandez H, Lucas C, Hedon B, Meyer JL, Mayenga JM, Roux C. One year comparison between two add-back therapies in patients treated with a GnRH-agonist for symptomatic endometriosis: a randomised double-blind trial. Hum Reprod 2004;19:1465–1471.
   PubMed Web of Science ®Google Scholar
• Bedaiwy MA, Casper RF. Treatment with leuprolide acetate and hormonal add-back for up to 10 years in stage IV endometriosis patients with chronic pelvic pain. Fertil Steril 2006;86:220–222.
   PubMed Web of Science ®Google Scholar
• Soysal S, Soysal ME, Ozer S, Gezgin T. The effects of post-surgical administration of goserelin plus anastrazole compared to goserelin alone in patients with severe endometriosis: a prospective randomised trial. Hum Reprod 2004;19:160–167.
   PubMed Web of Science ®Google Scholar
• Attar E, Bulun SE. Aromatase inhibitors: the next generation of therapeutics for endometriosis? Fertil Steril 2006;85:1307–1318.
   PubMed Web of Science ®Google Scholar
• Surrey ES. Steroidal and non-steroidal ‘add-back’ therapy: extending safety and efficacy of gonadotropin-releasing hormone agonists in the gynaecological patient. Fertil Steril 1995;64:673–685.
   PubMed Web of Science ®Google Scholar
• Palomba S, Russo T, Oriano F Jr, Tauchmanova EZ, et al Effectiveness of combined GnRH-analogue plus raloxifene administration in the treatment of uterine leiomyomas: a prospective, randomised, single-blind, placebo-controlled clinical trial. Hum Reprod 2002;17:3213–3319.
   PubMed Web of Science ®Google Scholar
• Wyatt , et al 2004.
   Google Scholar
• Palomba S, Orio F, Manguso F, Russo T, Falbo A, Lombardi G, Dolde P, Zullo F. Leuprolide acetate treatment with and without coadministration of tibolone in premenopausal women with menstrual cycle-related irritable bowel-syndrome. Fertil Steril 2005;83:1012–1020.
   PubMed Web of Science ®Google Scholar
• Perez-Medina T, Bajo J, Folgueira G, Ortega P. Atypical endometrial hyperplasia treatment with progestogens and gonadotropin-releasing hormone analogues: long-term follow-up. Gynecol Oncol 1999;73:299–304.
   PubMed Web of Science ®Google Scholar
• Agorastos T, Vaitsi V, Paschopoulos M, Vakiani A, Zoumatzi V, Saravelos H, Kostopoulou E, Constantinidis T, Dinas K, Vavilis D. Prolonged use of gonadotropin-releasing hormone agonist and tibolone as add-back therapy for the treatment od endometrial hyperplasia. Maturitas 2004;48:125–132.
   PubMed Web of Science ®Google Scholar
• Weitzel JN, Buys SS, Shermann WH, Daniels AN, Ursin G, Daniels R, MacDonald J, Blazer KR, Pike MC, Spicer D. Reduced mammographic density with use of a gonadotropin-releasing hormone agonist – based chemoprevention regimen in BRCA1 carriers. Clin Cancer Res 2007;13:654–658.
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, Prieshof B, Jackisch C, Paepke S, Kandel M, Schmutlzer R, Nestle-Kremmling C, Torode J, Kaufmann M. First experience with goserelin and ibandronate as medical prevention in premenopausal patients with increased familiary breast cancer risk: the GISS study. Eur J Cancer 2004;55(Suppl. 2): 44.
   Google Scholar
• Baum M, Hackshaw A, Houghton J, Rutqvist FT, Nordenskjold B, Nicolucci A, Sainsbury R. Adjuvant goserelin in premenopausal patients with early breast cancer: results from the ZIPP study. Eur J Cancer 2006;42:895–904.
   PubMed Web of Science ®Google Scholar
• Rossi E, Morabito A, de Maio E, Di Rella F, Esposito G, Gravina A, Labonia V, Landi G, Nuzzo F, Pacilio C. Endocrine effects of adjuvant letrozole + triptorelin compared with tamoxifen + triptorelin in premenopausal patients with early breast cancer. J Clin Oncol 2008;26:263–270.
   Web of Science ®Google Scholar
• Jannuzzo , Di Salle E, Spinelli R, Pirotta N, Buchanan P, Bello A. Estrogen suppression in premenopausal women following 8 weeks of treatment with exemestane and triptorelin versus triptorelin alone. Breast Cancer Res Treat 2009;13:491–499.
   Google Scholar
• Barbieri RL. Hormone treatment of endometriosis: the estrogen threshold hypothesis. Am J Obstet Gynecol 1992;166:740–745.
   PubMed Web of Science ®Google Scholar